Homeopathic medication and biologically active additive containing nisylen, cepa, euphrasia, belladonna and/or mericulis solubilis

FIELD: medicine.

SUBSTANCE: The invention relates to pharmacology, in particular, to medication for preventing or treating herpes labialis or herpes genitalis. The homeopathic medication or biologically active additive with anti-viral effect or preventing or treating herpes labialis or herpes genitalis contains: Nisylen, Cepa, Euphrasia, Belladonna and Mericulis Solubilis, furthermore, the components are present with a certain dilution and amount. The combination of the said components is used for production of homeopathic medication or biologically active additive with anti-viral effect or preventing or treating herpes labialis or herpes genitalis.

EFFECT: production of medication which effectively treats herpes labialis or herpes genitalis.

14 cl, 1 ex

 

The present invention relates to homeopathic medicinal product or biologically active additive to food containing Nisylen, Sulfur, Euphrasia, Belladonna and Mercurius solubilis, and to the use Nisylen, Sulfur, Euphrasia, Belladonna and Mercurius solubilis in homeopathic medicinal product or biologically active additive to food and to their production.

Nisylen ("nisylen) is known as a drug for use against influenza-like infections, high temperature, acute inflammation of the throat, headache and cough. This homeopathic remedy in the form of a complex preparation containing a variety of active substances and intended for oral administration in the form of tablets or solution. Active substances include Aconitum in homeopathic dilution (Dil.) D3, Gelsemium Dil. D3, Ipecacuanha Dil. D3, Phosphorus Dil. D5, Bryonia Dil. D2 and Eupatorium perfoliatum.

The use of Sulfur, Euphrasia, Belladonna and Mercurius solubilis in homeopathic medicines also well known.

The present invention is to show additional possible medical applications of the above components.

The invention is based on the knowledge that Nisylen, Sulfur, Euphrasia, Belladonna and Mercurius solubilis have antiviral activity, in particular, for the prevention or treatment of herpes labialis (cold sores on the lips or herpes genitalis (herpes mucous membrane of the urinary tract), antibact the branches, immunomodulatory and anti-inflammatory effects, and can also be used for prevention or treatment of prostate diseases, in particular for the treatment of prostatitis or degeneration of the prostate.

Herpes labialis is a viral disease caused by herpes simplex virus type I (HSV type I), in which the lips are formed small oozing bubbles, which are very sensitive, cause pain and itch and is very contagious.

Herpes genitalis is caused by a virus herpes simplex type II (HSV type II). In the case of herpes genitalis also bubbles filled with liquid, which cause severe pain, neuralgia and itching and also very contagious.

Both types of virus (HSV types I and II) affect the skin, mucous membranes, eyes, nervous system, and in rare cases even internal organs. Due to the fact that the virus is constantly present in the body, relapse, i.e. new outbreaks of disease may occur again and again. Of the currently known drugs apply virostatic that reduce the period of disease and partially relieve symptoms.

In the framework of the invention found that a homeopathic medicine or a biologically active food Supplement that contain a combination Nisylen, Sulfur, Euphrasia, Belladonna and Mercurius solubilis, exhibit antiviral activity and can be used, for example, about what ractice and treatment of herpes. In addition, in the framework of the invention it is also established that the homeopathic drug or biologically active food Supplement that contain Nisylen, Sulfur, Euphrasia, Belladonna and Mercurius solubilis, have antibacterial, immunomodulatory and anti-inflammatory action. Additionally, in the framework of the invention found that a homeopathic medicine or a biologically active food Supplement that contain Nisylen, Sulfur, Euphrasia, Belladonna and Mercurius solubilis, can be used for the prevention and treatment of prostate diseases such as prostatitis or degeneration of the prostate.

The following explanations relating to homeopathic medicinal products according to the invention are fully and to the biologically active additive to food in accordance with the invention.

The treatment of patients suffering from herpes labialis, and patients suffering from herpes genitalis, homeopathic medicinal product according to the present invention showed that the period of the disease was significantly reduced in both cases. The treatment of patients suffering from prostate cancer, homeopathic medicinal product according to the invention have shown that this significantly improves not only the index of PSA (PSA = prostate specific antigen), but the ratio of PSA. The ratio of free PSA to total PSA pristerene him in the serum of patients during diagnosis is considered as a measure of malignancy of the tumor. The smaller the ratio, the higher the degree of malignancy of the tumor.

The drug preferably is a homeopathic medicinal product.

In accordance with the invention can be provided by a homeopathic medicinal product, which contains as the main active ingredient of the following components: Nisylen, Sulfur, Euphrasia, Belladonna and Mercurius solubilis.

Sulfur (Latin name Luke) is also gomeopatichesky active substance, which is normally applied from the common cold (runny nose).

Euphrasia (eyebright) is known from the homeopathic substance that is typically used in diseases of the eye.

Currently, Belladonna (deadly nightshade) is applied in the form of homeopathic medicines in various forms of inflammation.

Mercurius solubilis (Mercurius solubilis) is a homeopathic medicinal product, which, as is well known, used in the treatment of, for example, acute inflammatory diseases of the throat, otitis and hoarseness.

Component Nisylen may contain the following ingredients: Aconitum napellus (monkshood pharmacy), Gelsemium sempervirens (Gelsemium evergreen), Cephaelis ipecacuanha (Ipecacuanha or ipecac and activated charcoal), Phosphorus (phosphorus), Bryonia (prestopino) and Eupatorium perfoliatum (Peconic pronsennolistny). Preferably, based on 1 g Nisylen ingredients included in the following the x quantities: 100 mg Aconitum napellus dilution D3, 100 mg Gelsemium sempervirens - D3, 100 mg Cephaelis ipecacuanha - D3, 100 mg Phosphorus - D5, 100 mg Bryonia - D2 and 100 mg Eupatorium perfoliatum - D1.

In accordance with the following aspect of the invention is possible in which contained in the homeopathic medicinal product Sulfur components, Euphrasia and Mercurius solubilis present in homeopathic dilution D12, and Belladonna in homeopathic dilution D15. In principle, it is possible to apply the active substance and other homeopathic dilutions.

Particularly preferred is a variant in which the component Nisylen present in the medicinal product in larger amounts or concentrations than other components.

Preferably homeopathic medication contains Nisylen, Sulfur, Euphrasia, Belladonna and Mercurius solubilis, while Nisylen present in homeopathic medicine in larger quantities than the other aforementioned components.

Particularly preferably, the component Nisylen was present in the amount from two to four times, mostly three times exceeds the amount of any of the other active substances of the homeopathic medicines.

In accordance with another aspect of the invention provides that the homeopathic medication contains Nisylen in weight from 4.0 to 4.5 g or in the amount of from 4.0 to 4.5 ml, preferably in the weight 4,286 g or volume 286 ml, and Sulfur, Euphrasia, Belladonna or Mercurius solubilis - in weight from 1.2 to 1.6 g or in the amount of from 1.2 to 1.6 ml each, mainly in the mass 1,429 g or volume 1,429 ml per 10 ml or 10 g of the solution or homeopathic medicines or biologically active food supplements.

It is possible to prepare homeopathic medicine for oral administration and/or for local use. The latter can be used, for example, for the treatment of herpes labialis.

In accordance with a preferred aspect of the homeopathic medicinal product may be liquid form, which can be an alcohol solution for oral administration. Besides alcohol, there are also other solutions. In principle, it is possible to ensure that homeopathic medicinal product in solid form, for example in the form of powder, tablets or pills. Similarly, you can ensure that homeopathic medicinal product in paste form or in the form of ointment.

Additional details and advantages of the invention are disclosed hereinafter with reference to the option described below for carrying out the invention.

Example 1

Homeopathic medicinal product according to the variant described here contains the following ingredients:

NisylenCepa D121,429
Euphrasia D121,429
Belladonna D151,429
Mercurius solubilis D121,429

These ingredients are present in the ethanol solution of 10 ml. As stated above, this solution is excellent for the treatment of herpes genitalis and herpes labialis, as well as for the treatment of prostate cancer.

It can be taken, for example, adults : 5 drops 3 times a day, and children under 2 drops 3 times a day. Particularly preferably, homeopathic medicine taken on a regular basis.

In the acute stage or preferably in the prodromal (i.e. pre-disease) stage is allowed to use tools every half an hour, i.e. once in half an hour, for example, 5 drops of solution (adults) or 2 drops (children).

It turned out that it is preferable not to dilute the solution and keep it in your mouth as long as possible. It was also shown that it is preferable to drink it in large quantities, if possible, about 3 l/day.

As mentioned above, the above-mentioned diseases (herpes) often give a relapse, which may occur one or more times a year, maybe every month is. Known medications help in the acute stage to shorten the course of illness and may relieve symptoms, but they are not able to prevent the occurrence of relapse. In addition to this sometimes occurs because the body's resistance to known drugs.

The present invention opens the possibility to achieve effective treatment of herpes genitalis and herpes labialis using particularly effective homeopathic medicines/biologically active food supplements. Equally effective treatment of prostate disease, particularly prostate or degeneration of the prostate.

In principle it is also possible deviations from the variant embodiment of the invention, described in detail above. The solvent need not necessarily be an alcohol solvent. In principle can be used also suitable for this purpose solvents. In addition, as stated above, the invention is not limited to the use of homeopathic medicines only in liquid form. Homeopathic medicinal product may be provided in solid form (tablets, powders, pills) or in the form of ointment.

1. Homeopathic medicine or dietary Supplement with antiviral action for the prevention or treatment of herpes labialis what do herpes genitalis, containing Nisylen, Sulfur, Euphrasia, Belladonna and Mercurius solubilis, and the components are Sulfur, Euphrasia and Mercurius solubilis present in the dilution D12, Belladonna - dilution D15, and the component Nisylen is present in the amount from two to four times, preferably three times, exceeds the amount of any of the other components.

2. Homeopathic medicine or dietary Supplement according to claim 1, characterized in that the homeopathic medication contains Nisylen in weight from 4.0 to 4.5 g or in the amount of from 4.0 to 4.5 ml, preferably in the weight 4,286 g or volume 4,286 ml, and Sulfur, Euphrasia, Belladonna and Mercurius solubilis - in weight from 1.2 to 1.6 g or volume from 1.2 to 1.6 ml each, preferably in mass 1,429 g or volume 1,429 g ml per 10 ml of solution.

3. Homeopathic medicine or dietary Supplement according to claim 1 or 2, characterized in that the homeopathic medicinal product is manufactured in liquid form.

4. Homeopathic medicine or dietary Supplement according to claim 3, characterized in that the homeopathic remedy is alcohol solution.

5. Homeopathic medicine or dietary Supplement according to claim 1 or 2, characterized in that the homeopathic medicinal product is manufactured in solid or pasty form.

6. Homeopathic Lek is rstone remedy or dietary Supplement according to claim 1 or 2, characterized in that the component Nisylen contains the following ingredients: Aconitum napellus, Gelsemium sempervirens, Cephaelis ipecacuanha, Phosphorus, Bryonia, and Eupatorium perfoliatum.

7. Homeopathic medicine or dietary Supplement according to claim 6, characterized in that at 1 g Nisylen ingredients are included in the following quantities: 100 mg Aconitum napellus - D3, 100 mg Gelsemium sempervirens - D3, 100 mg Cephaelis ipecacuanha - D3, 100 mg Phosphorus - D5, 100 mg Bryonia - D2 and 100 mg Eupatorium perfoliatum - D1.

8. Applying a combination of Nisylen, Sulfur, Euphrasia, Belladonna and Mercurius solubilis, where Sulfur components, Euphrasia and Mercurius solubilis present in the dilution D12, Belladonna - dilution D15, and the component Nisylen is present in the amount from two to four times, preferably three times, exceeds the amount of any of the other components, for the production of homeopathic medicinal products or food supplements with antiviral action for the prevention or treatment of herpes labialis or herpes genitalis.

9. The use of claim 8, where homeopathic medication contains Nisylen in weight from 4.0 to 4.5 g or in the amount of from 4.0 to 4.5 ml, preferably in the weight 4,286 g or 4,286 ml, and Sulfur, Euphrasia, Belladonna and Mercurius solubilis - in weight from 1.2 to 1.6 g or in the amount of from 1.2 to 1.6 ml each, preferably in mass 1,429 g or volume 1,429 g ml per 10 ml of solution.

10. The use of claim 8 or 9, where homeopathic medicine technology is toulene in liquid form.

11. The use of claim 10, where the homeopathic remedy is alcohol solution.

12. The use of claim 8 or 9, where the homeopathic medicinal product is manufactured in solid or pasty form.

13. The use of claim 8 or 9, where component Nisylen contains the following ingredients: Aconitum napellus, Gelsemium sempervirens, Cephaelis ipecacuanha, Phosphorus, Bryonia, and Eupatorium perfoliatum.

14. Use item 13, where 1 g Nisylen ingredients are included in the following quantities: 100 mg Aconitum napellus - D3, 100 mg Gelsemium sempervirens - D3, 100 mg Cephaelis ipecacuanha - D3, 100 mg Phosphorus - D5, 100 mg Bryonia - D2 and 100 mg Eupatorium perfoliatum - D1.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention is referred to the field of medicine, namely to dermatovenerology and immunology and can be used for treatment of patients with sexually transmitted urogenital infections caused by chlamydiae and/or micoplasma. It includes the infusion of antibiotics of macrolides group or immunotropic drug that is selected individually, for which purpose the sensitivity of patient to immunotropic drugs is determined. That is done by in vitro definition of interferons in the samples of peripheral blood and urogenital scrapings before and after addition of each studies drug. As the result the immunotropic drug selected for treatment is the one that induces the increase of interferon activity in studied material by no less than 4 U/ml compared to the baseline level in the samples of peripheral blood and urogenital scrapings.

EFFECT: method provides for etiologic recovery, prevention of disease relapses, particularly due to effective interferons production on systemic and local level.

1 dwg, 4 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention describes novel compounds of general formula in which is or (values of radicals are given in the claim), a method of producing said compounds, a pharmaceutical composition containing said compounds and therapeutic application thereof.

EFFECT: compounds are cysteine protease inhibitors and can be used in medicine.

25 cl, 1 tbl, 41 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly immunology, namely immunocorrection drugs, and can be used as an inducer of a granulocyte-macrophage colony-forming factor in cells of a mononuclear phagocyte system in vitro and for efferent therapy in pathological conditions accompanied by decrease in cell-mediated immunity. The drug represents oxidised dextrane of average molecular weight 35 - 65 kDa. The drug can be presented in the form of a solution or a nanoliposomal emulsion of the concentration of oxidised dextrane 1-5 wt %. The drug is applied by introduction in a cell culture of the mononuclear phagocyte system in an amount containing oxidised dextrane 125-250 mcg per culture medium 1 ml.

EFFECT: drug under the invention exhibits high biocompatibility.

8 cl, 1 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmaceutical industry, and concerns an immunomodulatory drug preparation showing antiviral properties. Substance of the invention consists in the fact that the offered drug preparation contains sodium nucleinate 2 to 50 mg/ml, sodium chloride 3 to 10 mg/ml and apyrogenic water with pH making within 6.0 to 7.5.

EFFECT: preparation has a direct antiviral effect, suppresses reproductive ability of viruses.

2 cl, 3 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to allergology, and can be used for prevention of development of respiratory allergies in a subject. That is ensured by introduction of an effective amount of Lactobacillus rhamnosus GG (LGG) either in a pregnant mother's body, and/or postnatal in a feeding mother's body, or in a subject directly.

EFFECT: introduction of LGG allows preventing an early allergic sensitisation and the following development of respiratory allergies due to higher production of serum antibodies IgA in a subject, and also prevention of allergic inflammation in lungs and respiratory ways.

12 cl, 13 ex, 9 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to optimised fused protein for blocking BLyS or APRIL, which contains extracellular region of N-end of truncated TACI (transmembrane activator and CAML-partner) and Fc sequence IgG. TACI segment of fused protein contains sequence of amino-end region of extracellular region, starting with 13-th amino acid residue, complete sequence of stem area from TACI and is obtained from native sequence of TACI between 12-th and 120-th amino acids. Segment Fc of immunoglobulin IgG of fused protein contains hinge region, CH2 region and CH3 region, TACI segment and Fc segment are fused either directly or through linker sequence. In addition, claimed is DNA sequence which codes fused protein, expression vector, host-cell, pharmaceutical composition, containing fused protein, and application of fused protein for blocking BLyS or APRIL. Obtained fused protein does not degrade in process of expression, possesses high biological activity and high level of expression.

EFFECT: fused protein in accordance with claimed invention can be used in treatment of diseases, associated with abnormal immunologic functions and in treatment of diseases caused by abnormal proliferation of B-lymphocytes.

10 cl, 6 dwg, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to immunomodulatory interleukin-1 drugs. An interleukin composition contains interleukin-1, a cyclooxygenase inhibitor - diclofenac, taken in certain proportions.

EFFECT: compositions exhibit higher efficacy and have no side effects.

6 cl, 5 tbl, 6 ex

Amide derivatives // 2427575

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (I), where m equals 1-2, and each R1 (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio, hydroxy-(2-6C)alkoxy, amino-(2- 6C)alkoxy, (1-6C)alkylamino-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di[(1-6C)alkyl]amino-(1-6C)alkyl, hydroxy-(2-6C)alkylamino, halogen-(2-6C)alkylamino, amino-(2-6C)alkylamino, (1-6C)alkoxy-(2-6C)alkylamino, (1-6C)alkylamino-(2-6C)alkylamino, di-[(1-6C)alkyl]amino-(2-6C)alkylamino, heterocyclyl, heterocyclyl-(1-6C)alkyl, heterocyclyloxy, heterocyclyl-(1-6C)alkoxy and heterocyclylamino, where heterocyclyl is a 3-7-member monocyclic saturated ring containing one or two heteroatoms selected from nitrogen, oxygen and sulphur, wherein the heterocyclyl can have 1-2 substitutes defined in claim 1, and any of the substitutes R1 given above, which contains a CH3 group bonded to a carbon or nitrogen atom, can contain a substitute given in claim 1, R2 is a halogen, trifluoromethyl or (1-6C)alkyl; R3 is hydrogen, and R4 is hydroxy, (1-6C)alkyl or (1-6C)alkoxy; or pharmaceutically acceptable salts thereof. The invention also relates to methods for synthesis of said compounds, pharmaceutical compositions based on said compounds, and use of said compounds in treating diseases or medical conditions mediated by cytokines.

EFFECT: more effective use of the compounds.

13 cl, 8 tbl, 15 ex

Heterocompound // 2425832

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula

or pharmaceutically acceptable salt thereof, where symbols assume the following values; ring denotes

or , X denotes a single bond, -CH2-, -NR3-, -O-, -S-, R1 denotes a halogen; phenyl; pyridyl; (C3-C8)cycloalkyl; or (C1-C6) alkyl or (C2-C6) alkenyl, each of which can contain a halogen, -CONH2, phenyl or (C3-C8)cycloalkyl as a substitute, R2 denotes CN, -O-(C1-C6)alkyl, -C(=O)H, halogen; or (C1-C6)alkyl, which can be substituted with a halogen or -OH, R3 can form morpholino or 1-pyrrolidinyl together with R1 and nitrogen, and when X denotes a single bond, R1 and R2 can jointly form a 5-member ring and additionally contain -(C1-C6)alkyl as a substitute, R4 denotes the following ring: , , , , , , , , , , or , where any one of the bonds in the ring is linked to an oxazole ring, R5 denotes -H, (C1-C6)alkyl, which can be substituted by not less than one group selected from: -C(=O)NRXRY, -NHRX and -ORX- (C2-C6)alkenyl-; -C(=O)H; -C(=O)NRXRY, RX and RY can be identical or different and denote -H; or (C1-C6)alkyl. The invention also relates to a pharmaceutical composition based on said compounds, having SlP1 agonist activity.

EFFECT: compounds and compositions can be used in medicine for preventing and treating rejection during organ transplant, bone marrow or tissue transplant and autoimmune diseases.

16 cl, 84 tbl, 198 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, also aims at treating babies suffering intestinal colics. A mother and a breast-fed child are treated simultaneously. A cephalosporin antibiotic, an antistaphylococcal immunoglobulin, a staphylococcal bacteriophage, an antifungal agent, a phagocytosis activator are prescribed in the mother for 7-10 days. A staphylococcal bacteriophage, Hylak forte are prescribed to the baby. The second stage involves prescribing a bacterial preparation, an immunomodulator and a therapeutic staphylococcal anatoxin. The baby intakes Hylak forte and the bacterial preparation.

EFFECT: method allows relieving intestinal colics and preventing the development of complications.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine, namely, to virology, pharmacy, and is intended for treatment of herpetic infections For this purpose applied is complex antiviral medication for external application, which contains (in wt %) recombinant interferon α - 2b (40-50) 106 IU, hyaluronic acid - 0.5-1.0, chitosan succinate - 1.0-2.0, licorice root extract - 0.2-0.5, zinc oxide - 0.8-2.0, lidocaine or dicaine - 0.8-1.0, polyethylenoxide-1500 - 5.0-7.0, anhydrous lanolin - 22.0-27.0, medical vaseline - 35.0-40.0, glycerin - 5.0-8.0, distillated water to 100,0 Medication ensures prolonged anti-inflammatory, anesthetic, wound-healing impact on herpetic affection of mucous membranes and skin, including genital herpes, opthalmo-herpes and shingles.

EFFECT: application of medication makes it possible to reduce terms of herpetic rash regress and reduce cytopathic effect of virus on skin and epithelium cells.

2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula where R1 is selected from H, F, CI, Br, CF3, C1-C6 alkoxy and OH; R2 is selected from H and C1-C6 alkyl; n equals 1-5; m equals 0 or 1; and Y is selected from CH2, NR3, (NR3R4)+X-, O and S; R3 and R4 are independently selected from H and C1-C4 alkyl; and X- is selected from pharmaceutically acceptable anions. The invention also relates to a method of producing said compound and to an antiviral pharmaceutical composition based on said compound of formula (I).

EFFECT: obtaining novel compounds and a composition based on said compounds, which can be used in medicine to treat a viral diseases such as herpes.

19 cl, 2 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to organic chemistry and specifically to novel derivatives of quinolone or one pharmaceutically acceptable salts thereof, solvates thereof or solvates of salts thereof, having general formula I , in which R1 denotes fluorine, R3 denotes halogen, a hydroxy group or a C1-C4-alkoxy group, R4 denotes C1-C6-alkyl or C3-C8-cycloalkyl, where the alkyl can contain 1-3 substitutes, and the substitutes are independently selected from a group comprising halogen or trifluoromethyl, and where the cycloalkyl can contain 1-3 halogen atoms as substitutes, or R3 and R4 together with atoms to which they are bonded form a ring with a group of formula , in which * indicates a site for bonding with a carbon atom, and # indicates a site for bonding with a nitrogen atom, R7 and R8 independently denote halogen, trifluoromethyl, a monofluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, C1-C3-alkyl or C1-C3-alkoxy group, and R9 denotes hydrogen, halogen or C1-C3-alkyl, or R8 denotes a trifluoromethoxy group, and R7 and R9 denote hydrogen, R10 denotes a group of formula or , in which * indicates a site for bonding with a carbon atom, R2 is bonded in position 3 or 4 and denotes a hydroxy group, hydroxycarbonyl, aminocarbonyl, C1-C4-alkyl, C1-C4-alkoxycarbonyl, C3-C6-cycloalkylcarbonyl or optionally hydroxy-substituted C1-C6-alkylaminocarbonyl, where the alkyl is substituted with one substitute and the substitute is selected from a group comprising a hydroxy group, hydroxycarbonyl, aminocarbonyl, C1-C4-alkoxycarbonyl and 2-oxopyrrolidin-1-yl, R5 and R6 are independently bonded in positions 3, 4 or 5 and independently denote hydrogen, hydroxy group, methyl or ethyl, and Y denotes a methylene group or an oxygen atom. The invention also relates to methods of producing a compound of formula I, a medicinal agent based on the compound of formula I, use of the compound of formula I and a method of fighting viral infections.

EFFECT: novel substituted quinolone derivatives which are useful in treating viral diseases are obtained.

11 cl, 1 tbl, 69 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine and is intended for treatment of lingering versions of jaundice course in newborn babies. UDCA preparations are administered in dose 20-30 mg/kg per day, therapy is carried out for not less than 3 months. Viferon suppositories are administered rectally. Day dose is 50 thousand units/kg. Scheme of introduction is 10 days-daily, after that every second day from 3 to 9-12 months. Cytomegalovirus is suppressed with application of medication aciclovir-akri and its analogues zovirax, valtrex for 21-30 days. To suppress causing agents of mycoplasmosis, ureaplasmosis and chlamidiosis, preparations from group of macrolids rovamicin and sumamed are administered. Scheme is: rovamicin in dose 100 thousand units/kg for 7 days, after that, sumamed with a single dose 10 mg/kg once, according to discontinuous scheme 1 time per week, for 3 weeks. Additionally applied are medications, enhancing phagocytocis: licopid, polyoxydonium, solution of dimephosphone in age doses.

EFFECT: method makes it possible to reduce treatment terms and avoid complications.

2 ex

FIELD: medicine.

SUBSTANCE: for treating urogenital clamidiosis, cytomegalovirus, herpes simplex, Helicobacter pylori, polyethylene oxide 1500 and polyethylene oxide 400 are melted in the ratio 9:1; the liquid melt is added with a design amount of the preservative sodium chloride; further a design amount of sodium deoxyribonucleate is added in mixing. A melted paste is mould to prepare Derinat suppositories of 1.3-2.5 g.

EFFECT: prepared suppositories provide high bioavailability and prolonged action of the active agent.

3 cl, 7 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: method involves introduction in a period of premonitory signs, not later than after the first 6 hours of the symptoms of genital and urogenital herpetic infection, a combination of two antiviral preparations: allokin-alpha 1 mg, once a day, every second day, a therapeutic course of 3 subcutaneous injections and oral single dose of famciclovir 1500 mg, and also external therapy of infagel 2 times a day for 5 days.

EFFECT: use of the invention enables reducing formation of vesicles and urogenital mucosal erosions, decreasing length of recurrences and a prolonged intercurrent period.

2 ex

FIELD: chemistry.

SUBSTANCE: compound of formula (I) has antiviral activity toward the human cytomegalovirus (HCMV) or some other representative of the Herpes virida group. In formula (I)

, R1 is a group of formula , where * denotes the point of bonding to a carbonyl group, R3 denotes a pyridyl which can be substituted with a substitute independently selected from a group comprising C1-C6alkyl or a cyano group, R5 and R6 independently denote hydrogen, R2 denotes a phenyl which can be substituted with a substitute selected from a group comprising a trifluoromethoxy group, a difluoromethoxy group and a monofluoromethoxy group, A is a group of formula

or , where * denotes the point of bonding to the carbonyl group, # denotes the point of bonding to the nitrogen atom of urea, R7 denotes C1-C6alkyl which can be substituted with a substitute selected from a group comprising C3-C6cycloalkyl, R8 and R9 independently denote hydrogen, halogen or C1-C6alkyl. The invention also relates to a method of producing a compound of formula (I) from a compound of formula , a method of producing a compound of formula (V), a medicinal agent containing the disclosed compound, use of the compound in preparing a medicinal agent and a method of fighting viral infections, among them human cytomegalovirus (HCMV) or some other representative of the Herpes viridae group.

EFFECT: high antiviral activity.

9 cl, 1 tbl, 39 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a stabilised liquid oxygen-release composition containing an ingredient (a) specified in salts consisting of An+ cations and anions produced of halogen oxides of general formula [OmX]- where A represents a metal specified in groups 1 or 2 of the periodic table, X means halogen atom, m=1-4, m=1 or 2, an ingredient (b) specified in a group of oxygen donors, an ingredient (c) specified in a group of stabilising agents for oxygen donors, and an ingredient (d) specified in a group of liquid binding agents with a molar ratio of the ingredient (b) to the ingredient (c) making 0.1-5.0(b):1.0(c). The stabilised liquid oxygen-release composition can be used in pharmaceutical compositions, cosmetic compositions and foodstuff, e.g., skin care products, dental care products, teeth wightening products, including chewing gums.

EFFECT: invention provides stability and prolonged action of the composition.

19 cl, 11 ex, 4 dwg

FIELD: chemistry.

SUBSTANCE: invention describes a sodium salt of 2-n-propylthio-6-nitro-1,2,4-triazole[5,1-c]-1,2,4-triazin-7(4H)-one dihydrate and a sodium salt of 2-n-butylthio-6-nitro-1,2,4-triazole[5,1-c]-1,2,4-triazin-7(4H)-one dihydrate having antiviral activity on herpes simplex virus HSV-1.

EFFECT: higher antiviral effect of the compounds.

1 cl, 1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: pharmaceutical composition for treating syphilis and viral diseases specified from influenza, human immunodeficiency virus, cytomegalovirus infections, viral hepatitis type A, D, C and herpes infections, containing an amount of polyphenol compounds of sea buckthorn leaves, including at least 60 % of halloellagotannines, flacoside, a pharmacologically acceptable carrier and a substance of licorice extract, or glycyrrhizic acid, or its pharmaceutically acceptable salt, acridonoacetic acid or its pharmaceutically acceptable salt, birch bark extract or betulin taken in therapeutically effective amounts. A method of treating syphilis and viral diseases, including the introduction of the declared pharmaceutical composition by 2-3 doses 3 times a day.

EFFECT: composition exhibits an evident antiviral action with respect to the infections stated above.

22 cl, 1 dwg, 12 tbl, 7 ex

Acid complex // 2442578

FIELD: pharmaceutical industry.

SUBSTANCE: invention relates to a complex for the antimicrobial and / or anti-inflammatory action, which contains fulvic acid having a molecular weight not exceeding 20 kDa herewith fulvic acid derived from sugar. The complex can also contains aluminum, mercury, cadmium, chromium and lead in amounts which do not harm human body. The invention also relates to a method of producing the specified complex which comprises dissolving the carbohydrate to form of a solution and oxidation of this carbohydrate in the water vapor. The obtained product, containing acidic components is subjected to filtration to remove acidic components with a molecular mass greater than 20 kDa.

EFFECT: invention provides complexes of fulvic acid, which practically does not contain harmful elements such as aluminum, chromium, mercury, other, and can be safely used in the pharmaceutical industry.

26 cl, 2 dwg, 1 tbl, 4, ex

Up!